These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38418776)

  • 21. Cancer risk of heterozygotes with the NBN founder mutation.
    Seemanová E; Jarolim P; Seeman P; Varon R; Digweed M; Swift M; Sperling K
    J Natl Cancer Inst; 2007 Dec; 99(24):1875-80. PubMed ID: 18073374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer variation associated with the position of the mutation in the BRCA2 gene.
    Lubinski J; Phelan CM; Ghadirian P; Lynch HT; Garber J; Weber B; Tung N; Horsman D; Isaacs C; Monteiro AN; Sun P; Narod SA
    Fam Cancer; 2004; 3(1):1-10. PubMed ID: 15131399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Random mutations' role in cancer.
    Cancer Discov; 2015 Apr; 5(4):OF3. PubMed ID: 25665809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogene's point mutation produces cancer.
    Hagen T
    JAMA; 1982 Nov; 248(19):2418-9, 2423-4. PubMed ID: 7131694
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer risks from germline p53 mutations.
    Frebourg T; Friend SH
    J Clin Invest; 1992 Nov; 90(5):1637-41. PubMed ID: 1430194
    [No Abstract]   [Full Text] [Related]  

  • 26. Does aneuploidy or mutation start cancer?
    Duesberg P
    Science; 2005 Jan; 307(5706):41. PubMed ID: 15637254
    [No Abstract]   [Full Text] [Related]  

  • 27. Genome Sequencing during a Patient's Journey through Cancer.
    Nangalia J; Campbell PJ
    N Engl J Med; 2019 Nov; 381(22):2145-2156. PubMed ID: 31774959
    [No Abstract]   [Full Text] [Related]  

  • 28. The mutation rate and cancer.
    Tomlinson IP; Novelli MR; Bodmer WF
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14800-3. PubMed ID: 8962135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer.
    Fox EJ; Salk JJ; Loeb LA
    Genome Med; 2016 Mar; 8(1):30. PubMed ID: 26987311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer mutation tied to scleroderma.
    Printz C
    Cancer; 2014 May; 120(9):1289. PubMed ID: 24756960
    [No Abstract]   [Full Text] [Related]  

  • 31. MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis.
    Jia P; Wang Q; Chen Q; Hutchinson KE; Pao W; Zhao Z
    Genome Biol; 2014; 15(10):489. PubMed ID: 25348067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond bad luck: induced mutations and hallmarks of cancer.
    Kelly-Irving M; Delpierre C; Vineis P
    Lancet Oncol; 2017 Aug; 18(8):999-1000. PubMed ID: 28759371
    [No Abstract]   [Full Text] [Related]  

  • 33. Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families.
    Renault AL; Mebirouk N; Cavaciuti E; Le Gal D; Lecarpentier J; d'Enghien CD; Laugé A; Dondon MG; Labbé M; Lesca G; Leroux D; Gladieff L; Adenis C; Faivre L; Gilbert-Dussardier B; Lortholary A; Fricker JP; Dahan K; Bay JO; Longy M; Buecher B; Janin N; Zattara H; Berthet P; Combès A; Coupier I; ; Hall J; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Carcinogenesis; 2017 Oct; 38(10):994-1003. PubMed ID: 28981872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lynch syndrome: the influence of environmental factors on extracolonic cancer risk in hMLH1 c.C1528T mutation carriers and their mutation-negative sisters.
    Blokhuis MM; Pietersen GE; Goldberg PA; Algar U; Van der Merwe L; Mbatani N; Vorster AA; Ramesar RS
    Fam Cancer; 2010 Sep; 9(3):357-63. PubMed ID: 20640520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypermutation in human cancer genomes: footprints and mechanisms.
    Roberts SA; Gordenin DA
    Nat Rev Cancer; 2014 Dec; 14(12):786-800. PubMed ID: 25568919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatic-cell mutations as a possible predictor of cancer risk.
    Akiyama M; Umeki S; Kusunoki Y; Kyoizumi S; Nakamura N; Mori T; Ishikawa Y; Yamakido M; Ohama K; Kodama T
    Health Phys; 1995 May; 68(5):643-9. PubMed ID: 7730060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation accumulation in vivo and the importance of genome stability in aging and cancer.
    Dollé ME; Giese H; van Steeg H; Vijg J
    Results Probl Cell Differ; 2000; 29():165-80. PubMed ID: 10838700
    [No Abstract]   [Full Text] [Related]  

  • 38. Mutation and cancer: a personal odyssey.
    Knudson AG
    Adv Cancer Res; 1995; 67():1-23. PubMed ID: 8571812
    [No Abstract]   [Full Text] [Related]  

  • 39. Cancer risks in LKB1 germline mutation carriers.
    Mehenni H; Resta N; Park JG; Miyaki M; Guanti G; Costanza MC
    Gut; 2006 Jul; 55(7):984-90. PubMed ID: 16407375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families.
    Cavaciuti E; Laugé A; Janin N; Ossian K; Hall J; Stoppa-Lyonnet D; Andrieu N
    Genes Chromosomes Cancer; 2005 Jan; 42(1):1-9. PubMed ID: 15390180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.